The Week of July 8 in Review
The week of July 8 in review, featuring clinical articles and videos on targeting the PI3K and AKT pathways, ASCO's CancerLinQ program, and ibrutinib in CLL and MCL.
Study of Lenalidomide in Newly Diagnosed Multiple Myeloma Patients Reaches Primary Endpoint
A phase III study of Revlimid in combination with dexamethasone in patients with newly diagnosed multiple myeloma met its primary endpoint of PFS.
New Drug Application Filed for Ibrutinib in Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma
The FDA has received a new drug application for ibrutinib as a therapy for previously treated CLL and previously treated MCL.
Pertuzumab and Trastuzumab Regimen in Neoadjuvant Setting for HER2-Positive Early Stage Breast Cancer Granted Priority Review
If approved, this regimen would be the first neoadjuvant regimen ever approved for the treatment of cancer.
The Case of The Wild Kinase
Learn how Genentech researchers Shiva Malek and Georgia Hatzivassiliou worked together to solve a mystery and change cancer research.
Mechanism of Action: Herceptin (Trastuzumab)
The mechanism of action of trastuzumab (Herceptin), a monoclonal antibody that is approved for the treatment of early-stage breast cancer that is HER2-positive.
The Week of June 24 in Review
The week of June 24 in review, featuring clinical articles and physician interviews on an FDA approval, crizotinib in NSCLC, sorafenib in DTC, and more.
FDA Approves Labeling Update for Dasatinib
The FDA approved an update to the product labeling for dasatinib (Sprycel), Bristol-Myers Squibb Company and Otsuka America Pharmaceutical announced on June 20.
High Response Rates to Ibrutinib Seen in CLL, MCL
Patients with chronic lymphocytic leukemia (CLL) and patients with mantle cell lymphoma (MCL) showed high response rates to therapy with ibrutinib.
Oncologists and Social Media: An Interview With Mike Thompson, MD, PhD
In advance of the 2013 ASCO Annual Meeting, Targeted Healthcare spoke with Mike Thompson, MD, PhD, about the use of social media in the field of oncology.
Elotuzumab Combination Demonstrates Benefit in Myeloma
Elotuzumab in combination with lenalidomide and low-dose dexamethasone showed efficacy in patients with previously treated multiple myeloma.
The Week of June 10 in Review
The week of June 10 in review, featuring stories and videos on testing for BRCA1/2, bevacizumab in cervical cancer, gene patenting, MPDL3280A in lung cancer, and more.
Supreme Court Decision Limits Gene Patenting
The US Supreme Court ruled that patents held on a test for genetic mutations associated with breast cancer is not eligible for patent protection.
Amgen Says Trebananib Improves Progression-Free Survival in Ovarian Cancer
A phase III study of the investigational peptibody trebananib has met its primary endpoint of an improvement in progression-free survival.
Mechanism of the cMET Pathway
The mechanisms of the cMET signaling pathway and potential therapeutic implications. After binding with its ligand, cMET activates a wide range of different cellular signaling pathways.
Underutilized Genetic Tests Put Families at Risk
Data from the French National Cancer Institute showed an increase in testing for BRCA1/2 for breast and ovarian cancer, though not for the MMR mutation for Lynch syndrome.
FDA Rejects Tivozanib for Advanced Renal Cell Carcinoma
The FDA rejected a new drug application for tivozanib, an inhibitor of vascular endothelial growth factor (VEGF), for the treatment of advanced renal cell carcinoma (RCC).
The Week of June 3 in Review
The week of June 3 in review, featuring content on crizotinib in NSCLC, an FDA approval, novel agents for the treatment of prostate cancer, and more.
Lenalidomide Approved by the FDA for the Treatment of Mantle Cell Lymphoma
Lenalidomide has been approved to treat patients with mantle cell lymphoma who have relapsed or whose disease has progressed after two prior therapies including at least one prior treatment with bortezomib.
Crizotinib Superior to Chemotherapy for Advanced ALK-Positive NSCLC
Crizotinib demonstrated superiority to chemotherapy for the treatment of previously treated, advanced non-small cell lung cancer (NSCLC) with ALK rearrangement in a trial published online by The New England Journal of Medicine.
The Week of May 27 in Review
The week of May 27 in review, featuring stories and videos on an FDA approval, T-DM1 for breast cancer, novel agents in early development, and the Notch pathway in gliomas.
FDA Approves Both Dabrafenib and Trametinib for Advanced Melanoma
The FDA approved both dabrafenib (Tafinlar) and trametinib (Mekinist) for the treatment of patients with metastatic or unresectable melanoma.
The Week of May 20 in Review
The week of May 20 in review, featuring stories and videos on biomarkers in prostate cancer, a phase III study halted after interim analysis, and priority review for Abraxane.
FDA Grants Abraxane Priority Review for the Treatment of Pancreatic Cancer
The FDA has granted priority review to paclitaxel protein-bound particles for injectable suspension, albumin-bound, or nab-paclitaxel, for metastatic pancreatic cancer when administered in combination with gemcitabine.
Study of Inotuzumab Ozogamicin Halted After Interim Analysis
A phase III study of inotuzumab ozogamicin for patients with relapsed or refractory CD22+ aggressive non-Hodgkin lymphoma who are not candidates for high-dose chemotherapy was halted after a scheduled interim analysis.
Mechanism of Action: Sorafenib
Sorafenib is small molecule inhibitor approved for the treatment of primary kidney cancer and advanced primary liver cancer.
SAR302503 Meets Primary Endpoint in JAKARTA Trial
The phase III JAKARTA trial of SAR302503 for myelofibrosis met its primary endpoint in both dose groups, as reported by Sanofi.
Potential Therapeutic Target Identified in Acute Myeloid Leukemia
Researchers have determined that high expression of microRNA-155 was associated with a poorer prognosis in patients with AML and that inhibition of a molecule that regulates the microRNA may serve as a therapeutic target for these patients.
The Week of May 13 in Review
The week of May 13 in review, featuring stories and videos on cabozantinib in medullary thyroid cancer, biomarkers in prostate cancer, and SAR302503 in myelofibrosis.
ASCO 2013 Abstract Roundup
Abstracts published in the Annual Meeting Proceedings Part I featuring late-stage data on ibrutinib, eribulin, regorafenib, sipuleucel-T, lambrolizumab, palbociclib, and more.
2 Clarke Drive Cranbury, NJ 08512